Details

Autor(en) / Beteiligte

• Riedel, Richard F.
• Ballman, Karla V.
• Lu, Yao
• Attia, Steven
• Loggers, Elizabeth T.
• Ganjoo, Kristen N.
• Livingston, Michael B.
• Chow, Warren
• Wright, Jennifer
• Ward, John H.
• Rushing, Daniel
• Okuno, Scott H.
• Reed, Damon R.
• Liebner, David A.
• Keedy, Vicki L.
• Mascarenhas, Leo
• Davis, Lara E.
• Ryan, Christopher
• Reinke, Denise K.
• Maki, Robert G.

Titel

A Randomized, Double‐Blind, Placebo‐Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment‐Refractory Liposarcoma: Results from the SARC024 Study

Ist Teil von

• The oncologist (Dayton, Ohio), 2020-11, Vol.25 (11), p.e1655-e1662

Ort / Verlag

Hoboken, USA: John Wiley & Sons, Inc

Erscheinungsjahr

2020

Quelle

Wiley-Blackwell Journals

Beschreibungen/Notizen

• Lessons Learned The results from the liposarcoma cohort of SARC024 confirm previously published data and do not support the routine use of regorafenib in this patient population. Continued exploration of novel therapies, including combination approaches, is warranted for a patient population in whom limited treatment options exist. Background Regorafenib is a multitargeted kinase inhibitor with a kinase profile overlapping, but distinct from, pazopanib, an agent approved for recurrent and metastatic non‐gastrointestinal stromal tumor (GIST), non‐adipocytic soft tissue sarcoma. We conducted a randomized, phase II study of regorafenib versus placebo in refractory liposarcoma patients. Methods Patients with advanced or metastatic, treatment‐refractory liposarcoma were randomized 1:1 to receive regorafenib 160 mg or placebo once daily (3 weeks on, 1 week off). Patients with well‐differentiated liposarcoma only were excluded. Crossover for placebo was allowed upon progression. The primary endpoint was progression‐free survival (PFS), according to RECIST version 1.1. Results Forty‐eight subjects with liposarcoma (34 dedifferentiated, 12 myxoid/round cell, 2 pleomorphic) were enrolled. Median PFS was 1.87 (95% confidence interval [CI], 0.92–3.67) months for regorafenib versus 2.07 (95% CI, 1.64–3.44) months for placebo; stratified hazard ratio [HR], 0.85 (95% CI, 0.46, 1.58), p = .62. No responses were seen on regorafenib. One PR was observed on placebo. Median overall survival was 6.46 (95% CI, 4.16–23.48) months for regorafenib and 4.89 (95% CI, 3.02–9.77) months for placebo, stratified HR, 0.66 (95% CI, 0.31–1.40), p = .28). Treatment‐related adverse events were similar to the known safety profile of regorafenib. Conclusion Regorafenib did not appear to improve PFS in treatment‐refractory liposarcoma. No new significant safety signals were observed.